Patient Perception of the Burden of Weight Gain and Blood Pressure Increase among RA Patients Using Celecoxib, Rofecoxib, and Non-specific NSAIDs

Frederick Wolfe, Kaleb Michaud, Sean Z. Zhao

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Nonsteroidal anti-inflammatory medications (NSAIDs) may be accompanied by clinically important renal side effects. We compared the rate of reported side effects from celecoxib, rofecoxib, and nonspecific (NS) NSAIDs and their burden in RA patients. Patients on rofecoxib were more likely to report a problem with weight gain (P < 0.05) and an increase in blood pressure (P < 0.001). In addition, rofecoxib users were 28% more likely to be in a more severe category for being bothered by unintentional weight gain (OR = 1.28, P < 0.05) and 53% more likely to state that they were in a more severe category for blood pressure increase (OR = 1.53, P < 0.000), compared with patients receiving celecoxib. Weight gain and blood pressure were also increased by coexisting cardiovascular disease. Clinicians should be aware that patient-reported weight gain and increases in blood pressure can occur with all NSAIDs, and may be particularly increased with rofecoxib. Existing cardiovascular disease is also an independent predictor of weight gain and increased blood pressure.

Original languageEnglish (US)
Pages (from-to)344-353
Number of pages10
JournalJournal of Clinical Rheumatology
Volume9
Issue number6
DOIs
StatePublished - Dec 1 2003

Fingerprint

Celecoxib
Weight Gain
Anti-Inflammatory Agents
Blood Pressure
Cardiovascular Diseases
rofecoxib
Kidney

Keywords

  • COX-2
  • Celecoxib
  • Edema
  • Hypertension
  • NSAID
  • Rofecoxib
  • Weight gain

ASJC Scopus subject areas

  • Rheumatology

Cite this

Patient Perception of the Burden of Weight Gain and Blood Pressure Increase among RA Patients Using Celecoxib, Rofecoxib, and Non-specific NSAIDs. / Wolfe, Frederick; Michaud, Kaleb; Zhao, Sean Z.

In: Journal of Clinical Rheumatology, Vol. 9, No. 6, 01.12.2003, p. 344-353.

Research output: Contribution to journalArticle

@article{5d80efe749ec4ffe8b6f9c68d5243760,
title = "Patient Perception of the Burden of Weight Gain and Blood Pressure Increase among RA Patients Using Celecoxib, Rofecoxib, and Non-specific NSAIDs",
abstract = "Nonsteroidal anti-inflammatory medications (NSAIDs) may be accompanied by clinically important renal side effects. We compared the rate of reported side effects from celecoxib, rofecoxib, and nonspecific (NS) NSAIDs and their burden in RA patients. Patients on rofecoxib were more likely to report a problem with weight gain (P < 0.05) and an increase in blood pressure (P < 0.001). In addition, rofecoxib users were 28{\%} more likely to be in a more severe category for being bothered by unintentional weight gain (OR = 1.28, P < 0.05) and 53{\%} more likely to state that they were in a more severe category for blood pressure increase (OR = 1.53, P < 0.000), compared with patients receiving celecoxib. Weight gain and blood pressure were also increased by coexisting cardiovascular disease. Clinicians should be aware that patient-reported weight gain and increases in blood pressure can occur with all NSAIDs, and may be particularly increased with rofecoxib. Existing cardiovascular disease is also an independent predictor of weight gain and increased blood pressure.",
keywords = "COX-2, Celecoxib, Edema, Hypertension, NSAID, Rofecoxib, Weight gain",
author = "Frederick Wolfe and Kaleb Michaud and Zhao, {Sean Z.}",
year = "2003",
month = "12",
day = "1",
doi = "10.1097/01.rhu.0000099744.85700.50",
language = "English (US)",
volume = "9",
pages = "344--353",
journal = "Journal of Clinical Rheumatology",
issn = "1076-1608",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Patient Perception of the Burden of Weight Gain and Blood Pressure Increase among RA Patients Using Celecoxib, Rofecoxib, and Non-specific NSAIDs

AU - Wolfe, Frederick

AU - Michaud, Kaleb

AU - Zhao, Sean Z.

PY - 2003/12/1

Y1 - 2003/12/1

N2 - Nonsteroidal anti-inflammatory medications (NSAIDs) may be accompanied by clinically important renal side effects. We compared the rate of reported side effects from celecoxib, rofecoxib, and nonspecific (NS) NSAIDs and their burden in RA patients. Patients on rofecoxib were more likely to report a problem with weight gain (P < 0.05) and an increase in blood pressure (P < 0.001). In addition, rofecoxib users were 28% more likely to be in a more severe category for being bothered by unintentional weight gain (OR = 1.28, P < 0.05) and 53% more likely to state that they were in a more severe category for blood pressure increase (OR = 1.53, P < 0.000), compared with patients receiving celecoxib. Weight gain and blood pressure were also increased by coexisting cardiovascular disease. Clinicians should be aware that patient-reported weight gain and increases in blood pressure can occur with all NSAIDs, and may be particularly increased with rofecoxib. Existing cardiovascular disease is also an independent predictor of weight gain and increased blood pressure.

AB - Nonsteroidal anti-inflammatory medications (NSAIDs) may be accompanied by clinically important renal side effects. We compared the rate of reported side effects from celecoxib, rofecoxib, and nonspecific (NS) NSAIDs and their burden in RA patients. Patients on rofecoxib were more likely to report a problem with weight gain (P < 0.05) and an increase in blood pressure (P < 0.001). In addition, rofecoxib users were 28% more likely to be in a more severe category for being bothered by unintentional weight gain (OR = 1.28, P < 0.05) and 53% more likely to state that they were in a more severe category for blood pressure increase (OR = 1.53, P < 0.000), compared with patients receiving celecoxib. Weight gain and blood pressure were also increased by coexisting cardiovascular disease. Clinicians should be aware that patient-reported weight gain and increases in blood pressure can occur with all NSAIDs, and may be particularly increased with rofecoxib. Existing cardiovascular disease is also an independent predictor of weight gain and increased blood pressure.

KW - COX-2

KW - Celecoxib

KW - Edema

KW - Hypertension

KW - NSAID

KW - Rofecoxib

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=0347386408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347386408&partnerID=8YFLogxK

U2 - 10.1097/01.rhu.0000099744.85700.50

DO - 10.1097/01.rhu.0000099744.85700.50

M3 - Article

C2 - 17043442

AN - SCOPUS:0347386408

VL - 9

SP - 344

EP - 353

JO - Journal of Clinical Rheumatology

JF - Journal of Clinical Rheumatology

SN - 1076-1608

IS - 6

ER -